We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.
days to go: Expired investment: £357,179
'Revolution Race Cars' is the brainchild of a team of British designers, engineers, and industry specialists. The company has produced an all-new race car: Revolution A-One that challenges not only the status quo but also changes the postcode. The car is created after eighteen months of R&D, rigorous selection, and 4,000 miles of extreme testing of Revolution's suppliers and partners. The official production of Revolution A-One started in May 2019, and its sales have already been recorded in three countries. With the proceeds, the company will optimise its production cycle for future expansion.
days to go: Expired investment: £392,220
Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
days to go: Expired investment: £1,493,593
Glovebox Direct is an online automotive parts, accessories and merchandise marketplace selling original equipment direct from the car and bike brands.
days to go: Expired investment: £181,670
An end-to-end digital platform providing aesthetic medical treatment in a market valued at almost £76bn. NowMe work closely with customers throughout the process by discussing the treatment they desire, selecting an appropriate medical practitioner from a UK Clinic and offering available finance solutions. The company is raising funds to refine their product and secure IP, as well as cover working capital requirements. The firm plan to launch in 2018 and by 2025 achieve international leadership.
days to go: Expired investment: £172,790
Developing ultra-efficient combustion cycles by replacing a conventional engine's mechanical drivetrain with cleaner and compact electrical components. Libertine have created Free Piston Engines that can operate by using either fossil fuels, or renewable energy. Their products have opportunities to provide benefits in numerous industries and the company has already had discussions with two large automotive firms and OEMs that are interested in utilising the technology. Libertine owns 28 patents and has distributed a license for its product, which is currently generating annual revenue growth of around 90%. Revenues in 2017 totalled £300k.
days to go: Expired investment: £710,970
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments. Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go: Expired investment: Withheld
MGB Biopharma is tackling the worldwide threat of antimicrobial resistance.   The company is in the process of clinical study and designing a new class of antibiotic.  They are looking for investment to start phase 2 of the study with 70% being supported by a grant.
days to go: Expired investment: £1,309,621
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go: Expired investment: £343,926
An innovation event that displays the greatest in medical healthcare technologies within exhibitions, conferences and workshops. GIANT Health has over 2000 delegates registered, with 235 speakers and 33 exhibitors whilst being sponsored by 8 global companies. Current revenue streams consist of event ticket sales, partnership packages, stage demos, etc. Events are held across Europe, with international expansion in the next phase.
days to go: Expired investment: £62,770
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph